Editorial: New Therapies in the Field of Rheumatology.
作者信息
Chighizola Cecilia Beatrice, Jakobsson Per-Johan, Gerosa Maria
机构信息
Experimental Laboratory of Immunorheumatological Researches, Unit of Allergology, Immunology and Rheumatology, IRCCS Istituto Auxologico Italiano, Milan, Italy.
Rheumatology Unit, Department of Medicine, Karolinska Institute, Solna, Sweden.
出版信息
Front Pharmacol. 2020 Jan 28;10:1604. doi: 10.3389/fphar.2019.01604. eCollection 2019.
Abstract
摘要
相似文献
1
Editorial: New Therapies in the Field of Rheumatology.社论：风湿病学领域的新疗法
Front Pharmacol. 2020 Jan 28;10:1604. doi: 10.3389/fphar.2019.01604. eCollection 2019.
2
Proposal for a new nomenclature of disease-modifying antirheumatic drugs.疾病修饰抗风湿药物新命名法建议。
Ann Rheum Dis. 2014 Jan;73(1):3-5. doi: 10.1136/annrheumdis-2013-204317. Epub 2013 Sep 26.
3
Patterns in use and costs of conventional and biologic disease-modifying anti-rheumatic drugs in Australia.澳大利亚传统和生物抗风湿药物的使用模式及成本
Clin Exp Rheumatol. 2017 Nov-Dec;35(6):907-912. Epub 2017 Apr 18.
4
Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?生物类类风湿关节炎治疗药物：我们是否需要更多的疗效比较数据？
BioDrugs. 2012 Apr 1;26(2):65-70. doi: 10.2165/11631320-000000000-00000.
5
Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis.类风湿关节炎治疗中常规改善病情抗风湿药物的应用进展。
Curr Opin Rheumatol. 2010 May;22(3):316-20. doi: 10.1097/BOR.0b013e3283383f87.
6
Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study.生物治疗中银屑病关节炎患者的治疗模式和医疗费用：一项回顾性队列研究。
Clin Ther. 2013 Sep;35(9):1376-85. doi: 10.1016/j.clinthera.2013.07.328. Epub 2013 Aug 15.
7
Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.类风湿关节炎生物制剂治疗患者在传统合成改善病情抗风湿药物间转换的经济负担及治疗模式
Clin Ther. 2016 May;38(5):1205-16. doi: 10.1016/j.clinthera.2016.03.013. Epub 2016 Apr 2.
8
[RHEUMATOLOGY - TIME FOR CHANGES].[风湿病学——变革之时]
Harefuah. 2017 Jul;156(7):408-410.
10
Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012.2003年至2012年间接受生物性改善病情抗风湿药治疗的类风湿关节炎患者基线疾病活动度的时间变化。
Mod Rheumatol. 2015 May;25(3):350-7. doi: 10.3109/14397595.2014.958274. Epub 2015 Jan 25.
本文引用的文献
1
Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review.生物制剂治疗红斑狼疮：文献综述。
Biomed Res Int. 2019 Jul 18;2019:8142368. doi: 10.1155/2019/8142368. eCollection 2019.
2
Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response.阿那白滞素在成人斯蒂尔病中的长期保留率及治疗反应的预测因素
Front Pharmacol. 2019 Apr 2;10:296. doi: 10.3389/fphar.2019.00296. eCollection 2019.
3
Growth and development of rheumatology in the United States--a bicentennial report. Presidential address to the American Rheumatism Association.美国风湿病学的发展历程——一份二百周年报告。在美国风湿病协会上的主席致辞。
Arthritis Rheum. 1977 Jul-Aug;20(6):1149-68. doi: 10.1002/art.1780200601.
Zotero 插件